4-chloro-N-(1-methylpiperidin-4-yl)phthalazin-1-amine | 1274713-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-chloro-N-(1-methylpiperidin-4-yl)phthalazin-1-amine
• CAS: 1274713-88-0
• 化学式: C₁₄H₁₇ClN₄
• mdl: MFCD17304206
• 分子量: 276.769
• InChiKey: ORPAWDKFBJNOTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-N-(1-methylpiperidin-4-yl)phthalazin-1-amine 在 sodium acetate trihydrate 、 溶剂黄146 作用下， 以88%的产率得到4-[(1-methylpiperidin-4-yl)amino]-2H-phthalazin-1-one
  参考文献：
  名称：

  Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors

  摘要：

  The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.027
• 作为产物：
  描述：

  邻苯二甲酰肼 在 sodium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-chloro-N-(1-methylpiperidin-4-yl)phthalazin-1-amine
  参考文献：
  名称：

  一类取代杂芳酞嗪衍生物的药学用途及其制备方法

  摘要：

  本公开涉及一种如式(I‑0)所示的取代杂芳酞嗪衍生物，其作为NLRP3抑制剂的用途及制备方法，其具有较好的NLRP3抑制活性。

  公开号：

  CN115417856A

文献信息

• Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
  作者：Anupreet Kharbanda、Lingtian Zhang、Debasmita Saha、Phuc Tran、Ke Xu、Ming O. Li、Yuet-Kin Leung、Brendan Frett、Hong-yu Li

  DOI：10.1016/j.ejmech.2021.113660

  日期：2021.11

  is one of vital clinical interest. Despite various attempts, there is still no FDA-approved therapy to inhibit the TGFβ pathway. Major mainstream approaches involve impairment of the TGFβ pathway via inhibition of the TGFβRI kinase. With the purpose to identify non-receptor kinase-based inhibitors to impair TGFβ signaling, an in-house chemical library was enriched, through a computational study, to

  TGFβ对于上皮和神经组织的稳态、伤口修复和调节免疫反应至关重要。其失调与大量疾病有关，其中改变肿瘤微环境是重要的临床意义之一。尽管进行了各种尝试，但仍然没有 FDA 批准的抑制 TGFβ 途径的疗法。主要的主流方法包括通过以下方式损伤 TGFβ通路抑制TGFβRI激酶。为了识别基于非受体激酶的抑制剂以损害 TGFβ 信号传导，通过计算研究丰富了内部化学库，以消除 TGFβRI 激酶活性。针对在 TGFβ-Smad 依赖性转录控制下用萤火虫荧光素酶基因改造的细胞系筛选选定的化合物。结果表明具有酞嗪核心的分子对 TGFβ-Smad 信号传导具有中等效力。合成了一系列酞嗪化合物并评估其效力。最有希望的化合物 ( 10p ) 的 IC 50为 0.11 ± 0.02 μM，经证实在高达 12 μM 时无细胞毒性，选择性指数约为 112 倍。同时，10p证实使用蛋白质印迹可减少 Smad 磷酸化，而不显示对
• 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
  申请人：成都奥睿药业有限公司

  公开号：CN115417856A

  公开（公告）日：2022-12-02

  本公开涉及一种如式(I‑0)所示的取代杂芳酞嗪衍生物，其作为NLRP3抑制剂的用途及制备方法，其具有较好的NLRP3抑制活性。
• Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors
  作者：Mohamed Elagawany、Mohamed A. Ibrahim、Hany Emary Ali Ahmed、A.Sh. El-Etrawy、Adel Ghiaty、Zakaria K. Abdel-Samii、Said A. El-Feky、Jürgen Bajorath

  DOI：10.1016/j.bmcl.2013.02.027

  日期：2013.4

  The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.